Bill

HR 3029

To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.

119th Congress Introduced by Sarah McBride and 3 co-sponsors

HR 3029 sets strict standards for handling nucleic acids to enhance biosecurity, impacting research institutions and biotech firms while ensuring public safety.

Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.

WeVote Research Nonpartisan

Bill Summary · HR 3029

Summary of HR 3029: Nucleic Acid Standards for Biosecurity Act

Purpose and Intent

The Nucleic Acid Standards for Biosecurity Act (HR 3029) aims to establish comprehensive standards and regulations concerning the handling, production, and distribution of nucleic acids. This legislation is designed to enhance biosecurity measures, ensuring that nucleic acids, which are critical components in genetic research and biotechnology, are managed in a manner that mitigates risks associated with their misuse or accidental release.

Key Provisions

The bill includes several significant provisions aimed at strengthening biosecurity protocols:

Establishment of Standards: The bill mandates the creation of standardized protocols for the synthesis, storage, and transportation of nucleic acids to ensure safety and security.
Regulatory Framework: It proposes a regulatory framework that would require entities involved in nucleic acid research and production to comply with specific biosecurity measures.
Oversight Mechanisms: The legislation calls for the establishment of oversight mechanisms to monitor compliance with the new standards, including potential penalties for non-compliance.
Collaboration with Agencies: The bill encourages collaboration between federal agencies, including the Department of Health and Human Services and the Department of Agriculture, to align biosecurity efforts across sectors.

Affected Parties

The following groups would be directly impacted by the provisions of HR 3029:

Research Institutions: Universities and laboratories conducting genetic research will need to adapt to the new standards.
Biotechnology Companies: Companies involved in the production and distribution of nucleic acids will face new regulatory requirements.
Government Agencies: Federal and state agencies responsible for biosecurity and public health will play a crucial role in implementing and enforcing the new regulations.

Legislative Timeline

Introduced: April 28, 2025
Referred to Committee: April 28, 2025 (House Committee on Science, Space, and Technology)
Committee Consideration: April 29, 2025 (Mark-up session held)
Ordered to be Reported: April 29, 2025 (by voice vote)

Conclusion

HR 3029 represents a proactive approach to biosecurity in the field of genetic research and biotechnology. By establishing clear standards and regulatory measures, the bill seeks to protect public health and safety while fostering responsible scientific innovation. As the bill progresses through the legislative process, its implications for research and industry practices will become clearer.

Compiled from official sources — confirm details with the bill’s official record.